YARTEMLEA is a fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement.

Importantly, inhibition of MASP-2 preserves the classical and alternative complement functions critical for defense against infection.

Omeros is pursuing approval in Europe for narsoplimab to treat TA-TMA.

To learn more, visit YARTEMLEA.com.

To view full Prescribing Information, click here.